Pharmacogenomics of heart failure: a systematic review.
Heart failure (HF) and multiple HF-related phenotypes are heritable. Genes implicated in the HF pathophysiology would be expected to influence the response to treatment.



We conducted a series of systematic literature searches on the pharmacogenetics of HF therapy to assess the current knowledge on this field.



Existing data related to HF pharmacogenomics are still limited. The ADRB1 gene is a likely candidate to predict response to β-blockers. Moreover, the cytochrome P450 2D6 coding gene (CYP2D6) clearly affects the pharmacokinetics of metoprolol, although the clinical impact of this association remains to be established.



Given the rising prevalence of HF and related costs, a more personalized use of HF drugs could have a remarkable benefit for patients, caregivers and healthcare systems.
Faculty of Pharmacy, Université de Montréal, Montreal, Canada.|Montreal Heart Institute, Montreal, Canada.
Fannie
F
Mottet
Associate Professor of Pharmacy & Medicine, University of Wisconsin-Madison, Madison, WI 53705, USA.
Orly
O
Vardeny
Faculty of Pharmacy, Université de Montréal, Montreal, Canada.|Montreal Heart Institute, Montreal, Canada.
Simon
S
de Denus
D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000627:therapeutic use; D019389:Cytochrome P-450 CYP2D6 / Q000235:genetics; D006333:Heart Failure / Q000188:drug therapy*; D006801:Humans; D010597:Pharmacogenetics; D011110:Polymorphism, Genetic; D018342:Receptors, Adrenergic, beta-1 / Q000235:genetics
D000319:Adrenergic beta-Antagonists; D000806:Angiotensin-Converting Enzyme Inhibitors; D018342:Receptors, Adrenergic, beta-1; D019389:Cytochrome P-450 CYP2D6